8-K: Tharimmune Announces 1-for-15 Reverse Stock Split to Regain Nasdaq Compliance

Tharimmune, Inc. has announced a 1-for-15 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement, effective May 24, 2024.

Summary

• Tharimmune, Inc. has filed a Certificate of Amendment to its Certificate of Incorporation to effect a 1-for-15 reverse stock split of its common stock.
• The reverse stock split will be effective at 4:01 p.m. Eastern Time on May 24, 2024.
• Trading on a post-split basis will commence on May 28, 2024, under the existing trading symbol THAR.
• The primary reason for the reverse stock split is to meet Nasdaq's $1.00 per share minimum bid price requirement for continued listing.
• Following the reverse stock split, the company will have approximately 785,978 shares of common stock issued and outstanding.
• A proportionate adjustment will be made to outstanding equity-based awards and other equity rights.

Sentiment

Score: 4

Explanation: The sentiment is negative due to the reverse stock split being a consequence of a low share price and the risk of not regaining compliance with Nasdaq listing requirements. While the company is taking action, the underlying situation is concerning.

Positives

• The reverse stock split is a proactive measure to address Nasdaq's minimum bid price requirement.
• The company is taking steps to maintain its listing on the Nasdaq Capital Market.

Negatives

• The reverse stock split is a result of the company's share price falling below the Nasdaq minimum bid price requirement.
• There is no guarantee that the reverse stock split will enable the company to regain compliance with the Nasdaq minimum bid price requirement.

Risks

• There is no assurance that the reverse stock split will enable the Company to regain compliance with the Nasdaq minimum bid price requirement.
• The company's share price may continue to fluctuate and could potentially fall below the minimum bid price again in the future.
• The reverse stock split could negatively impact investor sentiment.

Future Outlook

The company intends to maintain its Nasdaq listing, but there is no guarantee that the reverse stock split will achieve this.

Management Comments

• The reverse stock split was approved by Tharimmune stockholders at the Annual Meeting of Stockholders held on May 14, 2024.
• The final ratio was determined by the Company's Board of Directors.

Industry Context

Reverse stock splits are a common strategy for companies facing delisting from major exchanges due to low share prices, particularly in the biotechnology sector where stock prices can be volatile.

Comparison to Industry Standards

• Many biotechnology companies with low share prices have used reverse stock splits to maintain their listing on major exchanges.
• For example, companies like Agenus Inc. and Ocugen Inc. have recently implemented reverse stock splits to meet Nasdaq's minimum bid price requirement.
• The 1-for-15 ratio is within the typical range for reverse stock splits, which can vary from 1-for-2 to 1-for-20 or more.

Stakeholder Impact

• Shareholders will see a reduction in the number of shares they own, but the value of their holdings should remain the same immediately after the split.
• The reverse stock split may impact investor confidence and potentially lead to further price volatility.

Next Steps

• The company will begin trading on a post-split basis on May 28, 2024.
• The company will monitor its share price to ensure continued compliance with Nasdaq listing requirements.

Key Dates

Keywords

reverse stock split, Nasdaq compliance, minimum bid price, THAR, common stock, biotechnology, equity awards